European payers question value of new cancer drugs
Debi wrote an interesting post today on
Here’s a quick excerpt
Cancer is the fastest-growing section of the drugs market but developing new treatments is only half the battle. Persuading payers to use them, particularly in Europe, is another matter.
Yet use of both these medicines remains controversial in key European markets, where state-backed healthcare systems are struggling with the escalating cost of cancer treatments.
Read the rest of this great post here